TargetBeta
CHRM5
cholinergic receptor muscarinic 5 · Cholinergic receptors muscarinic
1 program in company-led studies act on CHRM5, from 1 company: 0 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Glycopyrrolaterule | Novartis | phase 4 | 873 running | CHRM1, CHRM2, CHRM3, CHRM4 | ChEMBL |
Conditions their studies are in
- Asthma, 1 program
- Hyperhidrosis, 1 program
- Pulmonary Disease, Chronic Obstructive, 1 program
- Renal Insufficiency, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- May 31, 2027Glycopyrrolate · Novartis · phase 4 · NCT07073950
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.